Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 862 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Cognitive behavioral therapy (CBT), Relaxation techniques and education about ADHD
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Occupational Therapy via Telehealth, Standard of Care Occupational Therapy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
ADHD
Interventions
Concerta, Adderall-XR
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Brookline, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Immediate-Release Viloxazine in Adults With ADHD

NCT01107496
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
IR Viloxazine, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Digital Treatment
Other
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Garden Grove, California • Lauderhill, Florida + 11 more
Conditions
Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Atomoxetine
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 11 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
6 Years to 17 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Enrolling by invitation Not applicable Interventional

Mindfulness ADHD Intervention

NCT07037030
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Guided deep breathing
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 11 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Brookline, Massachusetts
Enrolling by invitation Not applicable Interventional

Parent-Educator Action Response

NCT07203014
Conditions
Attention Deficit and Disruptive Behavior Disorders
Interventions
Parent-Educator Action Response (PEAR), Daily Report Card
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain Dopamine Function in Adults With ADHD

NCT00580814
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Experimental: methylphenidate treatment
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Irvine, California
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rolling Hills Estates, California + 49 more
Completed Phase 4 Interventional

Inuniv and Working Memory

NCT01177306
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
extended release guanfacine
Drug
Lead sponsor
Lori A. Schweickert, MD
Individual
Eligibility
8 Years to 12 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cary, North Carolina
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, Delaware
Completed Not applicable Interventional Accepts healthy volunteers

Improving Behavioral Health Care for Children With ADHD

NCT02972086
Conditions
ADHD
Interventions
Behavioral Parent Training (BPT)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
4 Years to 5 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more
Conditions
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Interventions
Centanafadine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Gainesville, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
Completed Not applicable Interventional Results available

PK/PD Pediatric ADHD Classroom Study

NCT02536105
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate HCl ER tablets 1, Placebo, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Las Vegas, Nevada
Conditions
Neurodevelopmental Disorders, Intellectual Disability, Development Delay, ADHD, Autism Spectrum Disorder, Epilepsy
Interventions
Sulfonylurea
Drug
Lead sponsor
Royal Devon and Exeter NHS Foundation Trust
Other
Eligibility
2 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
ADHD
Interventions
Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
33
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 27 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
high dose clonidine HCl sustained release, low dose clonidine HCl sustained release, placebo
Drug
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Gainesville, Florida • Jacksonville, Florida • Miami, Florida + 9 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Beverly Hills, California • Garden Grove, California • National City, California + 11 more
Completed Not applicable Interventional Accepts healthy volunteers

Obesity Treatment Enhanced With Working Memory Training

NCT02529397
Conditions
ADHD, Weight Loss
Interventions
Adaptive Working Memory Training, Non-adaptive cognitive training
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
Monarch Medical Research
Other
Eligibility
6 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia